Pharmaniaga MD Zulkifli Jafar is optimistic that the facility would strengthen Pharmaniaga’s balance sheet.
PETALING JAYA: Pharmaniaga Bhd
’s newly launched biopharmaceutical plant is expected to contribute 30% to 35% to gross profit margin for the 2026 financial year (FY26).
The facility, located in Puchong here will be the first locally owned biopharmaceutical plant in Malaysia.
Pharmaniaga managing director Zulkifli Jafar said the plant, which manufactures human insulin and vaccines, will commence operations in 2026.
“We are looking at a revenue of at least RM100mil per annum for insulin and RM300mil for vaccines. So, (the facility) is contributing almost RM400mil,” he said after launching the plant yesterday.
Certified by the European Union good manufacturing practice, he said the plant’s annual capacity is 30 million doses of human insulin, exceeding Malaysia’s demand of about 25 million.
He is optimistic that the facility would strengthen Pharmaniaga’s balance sheet.
The plant, currently undergoing simulation procedures, is seeking regulatory authorities’ approval. — Bernama
